Document Detail

Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I).
MedLine Citation:
PMID:  15979439     Owner:  NLM     Status:  MEDLINE    
Early results with polymer-based paclitaxel-eluting stents have shown significant improvements in the clinical and angiographic parameters of restenosis, as well as excellent safety outcomes. However, the duration of these beneficial effects is unknown. Therefore, the clinical outcomes of the TAXUS I study population were evaluated at 2- and 3-year follow-up. In TAXUS I, 61 patients with single, focal coronary lesions were randomly assigned to receive either a paclitaxel-eluting TAXUS stent (n = 31) or a bare metal control stent (n = 30). Low rates of composite major adverse cardiac events (MACEs) reported at 1-year follow-up (3.2% TAXUS vs 10.0% control) were maintained at 2 and 3 years, with no additional MACEs in either treatment group 1 year after implantation. The single target vessel revascularization in the TAXUS group was remote from the target lesion in contrast to 3 target lesion revascularizations in the control group.
Eberhard Grube; Sigmund Silber; Karl Eugen Hauptmann; Lutz Buellesfeld; Ralf Mueller; Victor Lim; Ulrich Gerckens; Mary E Russell
Related Documents :
12222999 - Balloon angioplasty in chronic critical limb ischemia: factors affecting clinical and a...
11835639 - Patterns of in-stent restenosis after placement of nir gold-coated stents in unselected...
15282429 - Results of intracoronary beta-brachytherapy administered by 60 mm transfer device/radia...
1414929 - Influence of vessel selection on the observed restenosis rate after endoluminal stentin...
12972119 - Effectiveness of treatment of in-stent restenosis with an 8-french compatible atherecto...
17139669 - Incidence and predictors of recurrent restenosis following implantation of drug-eluting...
19101239 - Cardiac transplantation for cardiac sarcoidosis with initial diagnosis by examination o...
18657679 - Platelet inhibitor therapy: current perspectives and emerging novel agents: introduction.
10918289 - Radio frequency transmyocardial revascularization enhances angiogenesis and causes myoc...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of cardiology     Volume:  96     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2005 Jul 
Date Detail:
Created Date:  2005-06-27     Completed Date:  2005-08-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  79-82     Citation Subset:  AIM; IM    
Heart Center Siegburg, Siegburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Phytogenic / administration & dosage*,  adverse effects,  therapeutic use*
Coronary Restenosis / prevention & control*
Coronary Stenosis / therapy*
Follow-Up Studies
Middle Aged
Paclitaxel / administration & dosage*,  adverse effects,  therapeutic use*
Polymers / chemistry
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Polymers; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intravascular ultrasonic assessment of stent diameters derived from manufacturer's compliance charts...
Next Document:  Association between consumption of beer, wine, and liquor and plasma concentration of high-sensitivi...